Key result
DOAC initiation at discharge for new AF is linked to ~39% lower 3-year MACE risk.
Why the study?
Anticoagulation initiation with DOACs at hospital discharge in patients with newly diagnosed AF involves balancing early bleeding risk and long-term stroke prevention, but data guiding this practice remain limited.
Does DOAC initiation at discharge reduce MACE and NACE in hospitalized adults with newly diagnosed atrial fibrillation?
Cohort (n=16,641)
Does DOAC initiation at discharge reduce MACE and NACE in hospitalized adults with newly diagnosed atrial fibrillation?
Hazard Ratio: 0.61 (95% CI 0.58–0.65)
p-value: p=<0.001
Initiation of DOACs at hospital discharge for newly diagnosed atrial fibrillation is associated with lower early and long-term risks of ischemic and net adverse clinical events.
New-onset atrial fibrillation (AF) is common among acutely hospitalized patients and is associated with increased risks of stroke and mortality. However, anticoagulation in this setting involves a temporal tradeoff between early bleeding during recovery and potential long-term stroke prevention, and data guiding direct oral anticoagulant (DOAC) initiation at discharge remain limited. We conducted a retrospective cohort study of adults with newly diagnosed AF identified between 3 days before hospital admission and hospital discharge within the Baylor Scott & White Health system (July 2020-June 2024), comparing patients initiated on DOAC therapy at discharge with those who were not. Outcomes included major adverse cardiovascular events (MACE: all-cause death, non-fatal myocardial infarction, or ischemic stroke/transient ischemic attack) and net adverse clinical events (NACE: MACE or major bleeding) at 30 days and 3 years. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs), and landmark cumulative incidence analyses assessed temporal trends after discharge. Among 16,641 patients (mean age 75.1 years; 41.8% women), 7,181 (43.2%) were discharged on a DOAC. In adjusted analyses, DOAC use was associated with lower risk of 3-year MACE (HR 0.61; 95% CI 0.58-0.65; p<0.001) and NACE (HR 0.64; 95% CI 0.61-0.68; p<0.001) compared with those not receiving DOAC therapy. Landmark analyses showed consistent reductions in MACE at both 30 days (HR 0.61; 95% CI 0.57-0.65) and 3 years (HR 0.68; 95% CI 0.62-0.74). Patients treated with DOACs had a lower risk of NACE at both 30 days (HR 0.65; 95% CI 0.61-0.69) and 3 years (HR 0.67; 95% CI 0.62-0.73). Overall, DOAC initiation at discharge in patients with newly diagnosed AF identified between 3 days before hospital admission and hospital discharge was associated with lower early and long-term ischemic risk, with lower rates of both MACE and NACE observed at 30 days and 3 years, underscoring the need for individualized decision-making regarding anticoagulation during acute hospitalization.
No takes yet. Share an insight, caveat, or question.
Cervantes et al. (2026) conducted a cohort in Newly diagnosed Atrial Fibrillation (n=16,641). DOAC therapy at discharge vs. No DOAC therapy at discharge was evaluated on 3-year major adverse cardiovascular events (MACE: all-cause death, non-fatal myocardial infarction, or ischemic stroke/transient ischemic attack) (HR 0.61, 95% CI 0.58-0.65, p=<0.001). DOAC initiation at discharge for newly diagnosed atrial fibrillation was associated with a lower risk of 3-year MACE compared to no DOAC therapy (HR 0.61; 95% CI 0.58-0.65; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: